Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Health inequalities: breaking down barriers to cancer screening September 23, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab May 17, 2022 ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current... May 19, 2021 ESMO World Congress on Gastrointestinal Cancer 2020 June 22, 2020 Load more HOT NEWS Can Cancer Symptoms Be Mistaken for Menopause? EMA Adopts a New Pharmaceutical Form of Selumetinib Holiday Travel: 11 Things To Know Before Hitting The Road With... How we are working with industry to translate research into real...
